These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 29472524)
1. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. Zhang K; Chen J; Zhou H; Chen Y; Zhi Y; Zhang B; Chen L; Chu X; Wang R; Zhang C Cell Death Dis; 2018 Feb; 9(3):312. PubMed ID: 29472524 [TBL] [Abstract][Full Text] [Related]
2. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282 [TBL] [Abstract][Full Text] [Related]
3. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
4. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343 [TBL] [Abstract][Full Text] [Related]
5. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144 [TBL] [Abstract][Full Text] [Related]
6. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line. Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286 [TBL] [Abstract][Full Text] [Related]
7. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114 [TBL] [Abstract][Full Text] [Related]
8. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1. Guo XL; Wang HB; Yong JK; Zhong J; Li QH Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839 [TBL] [Abstract][Full Text] [Related]
9. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway. Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705 [TBL] [Abstract][Full Text] [Related]
11. LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma. Li X; Zhou Y; Yang L; Ma Y; Peng X; Yang S; Li H; Liu J J Cell Physiol; 2020 Apr; 235(4):3402-3413. PubMed ID: 31549407 [TBL] [Abstract][Full Text] [Related]
12. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5. Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554 [TBL] [Abstract][Full Text] [Related]
13. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy. Wang D; Yang J Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178 [TBL] [Abstract][Full Text] [Related]
14. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254 [TBL] [Abstract][Full Text] [Related]
15. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. Song W; Zheng C; Liu M; Xu Y; Qian Y; Zhang Z; Su H; Li X; Wu H; Gong P; Li Y; Fan H Mol Ther; 2021 Aug; 29(8):2601-2616. PubMed ID: 33839325 [TBL] [Abstract][Full Text] [Related]
16. MiR-30e-3p Influences Tumor Phenotype through Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093 [TBL] [Abstract][Full Text] [Related]
17. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib. Zhang Y; Pan Q; Shao Z Hum Cell; 2023 Jan; 36(1):296-311. PubMed ID: 36424471 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
19. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis. Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]